Antibiotics for the treatment of rheumatoid arthritis

International Journal of General Medicine

Volumn 7, Issue , 2013, Pages 43-47

  Ogrendik, Mesut ^a  

^a Nazilli State Hospital   (Turkey)

Author keywords

Disease modifying antirheumatic drugs; Oral bacteria; Periodontitis; Treatment

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; LEVOFLOXACIN; MACROLIDE; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; PLACEBO; ROXITHROMYCIN; SALAZOSULFAPYRIDINE; SULFAMETHOXAZOLE; TETRACYCLINE;

ABDOMINAL PAIN; ALLERGIC REACTION; ANOREXIA; BRAIN PSEUDOTUMOR; CLINICAL EFFECTIVENESS; CONSTIPATION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; EOSINOPHILIA; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; INSOMNIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MOTION SICKNESS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; QUALITY OF LIFE; RASH; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; SMELLING DISORDER; SPERMATOGENESIS; STEVENS JOHNSON SYNDROME; SUNBURN; SYSTEMIC LUPUS ERYTHEMATOSUS; TASTE DISORDER; TENDINITIS; TENDON RUPTURE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT PLANNING; URTICARIA; VERTIGO; VOMITING; XEROSTOMIA;

EID: 84891599053     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S56957     Document Type: Review

References (38)

1. Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med. 1999;131(10):768-774.
2. Svartz N. The treatment of rheumatic polyarthritis with acid azo compounds. Rheumatism. 1948;4(1):180-185.
3. Brown TM, Clark HW, Bailey JS, Gray CW. A mechanistic approach to treatment of rheumatoid type arthritis naturally occurring in a gorilla. Trans Am Clin Climatol Assoc. 1971;82:227-247.
4. Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum. 1994;37(5):629-636.
5. Tilley BC, Alarcón GS, Heyse SP, et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med. 1995;122(2):81-89.
6. O'Dell JR, Haire CE, Palmer W, et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1997;40(5):842-848.
7. O'Dell JR, Blakely KW, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum. 2001;44(10):2235-2241.
8. Ogrendik M, Kokino S, Ozdemir F, Bird PS, Hamlet S. Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritis. Med Gen Med. 2005;7(2):2.
9. Moen K, Brun JG, Valen M, et al. Synovial inflammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs. Clin Exp Rheumatol. 2006;24(6):656-663.
10. Lundberg K, Kinloch A, Fisher BA, et al. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum. 2008;58(10): 3009-3019.
11. Mikuls TR, Payne JB, Reinhardt RA, et al. Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. Int Immunopharmacol. 2009;9(1):38-42.
12. Martinez-Martinez RE, Abud-Mendoza C, Patiño-Marin N, Rizo-Rodríguez JC, Little JW, Loyola-Rodríguez JP. Detection of periodontal bacterial DNA in serum and synovial fluid in refractory rheumatoid arthritis patients. J Clin Periodontol. 2009;36(12):1004-1010.
13. Bartold PM, Marino V, Cantley M, Haynes DR. Effect of Porphyromonas gingivalis-induced inflammation on the development of rheumatoid arthritis. J Clin Periodontol. 2010;37(5):405-411.
14. Cantley MD, Haynes DR, Marino V, Bartold PM. Pre-existing periodontitis exacerbates experimental arthritis in a mouse model. J Clin Periodontol. 2011;38(6):532-541.
15. Kinloch AJ, Alzabin S, Brintnell W, et al. Immunization with Porphyromonas gingivalis enolase induces autoimmunity to mammalian α-enolase and arthritis in DR4-IE-transgenic mice. Arthritis Rheum. 2011;63(12):3818-3823.
16. Reichert S, Haffner M, Keyßer G, et al. Detection of oral bacterial DNA in synovial fluid. J Clin Periodontol. 2013;40(6):591-598.
17. McConkey B, Amos RS, Durham S, Forster PJ, Hubball S, Walsh L. Sulphasalazine in rheumatoid arthritis. Br Med J. 1980;280(6212): 442-444.
18. Hoult JR. Pharmacological and biochemical actions of sulphasalazine. Drugs. 1986;32 Suppl 1:18-26.
19. Pullar T, Hunter JA, Capell HA. Which component of sulphasalazine is active in rheumatoid arthritis? Br Med J (Clin Res Ed). 1985;290(6481): 1535-1538.
20. Ash G, Baker R, Rajapakse C, Swinson DR. Study of sulphamethoxazole in rheumatoid arthritis. Br J Rheumatol. 1986;25(3):285-287.
21. Ostrander FD. Vitamins, sulfonamides and antibiotics in periodontal therapy. J Am Dent Assoc. 1948;37(3):279-288.
22. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum. 1992;35(10):1117-1125.
23. Weinblatt ME, Reda D, Henderson W, et al. Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials. J Rheumatol. 1999;26(10):2123-2130.
24. Scott DL, Dacre JE. Adverse reactions to sulfasalazine: the British experience. J Rheumatol Suppl. 1988;16:17-21.
25. Alarcón GS. Tetracyclines for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2000;9(7):1491-8.
26. Nakao R, Takigawa S, Sugano N, et al. Impact of minocycline ointment for periodontal treatment of oral bacteria. Jpn J Infect Dis. 2011;64(2):156-160.
27. Kwiatkowska B, Maslinska M. Macrolide therapy in chronic inflammatory diseases. Mediators Inflamm. 2012;2012:636157.
28. Ogrendik M. Effects of clarithromycin in patients with active rheumatoid arthritis. Curr Med Res Opin. 2007;23(3):515-522.
29. Saviola G, Abdi Ali L, Rossini P, et al. Clarithromycin in rheumatoid arthritis patients not responsive to disease-modifying antirheumatic drugs: an open, uncontrolled pilot study. Clin Exp Rheumatol. 2002;20(3):373-378.
30. Saviola G, Abdi-Ali L, Campostrini L, et al. Clarithromycin in rheumatoid arthritis: the addition to methotrexate and low-dose methylprednisolone induces a significant additive value-a 24-month single-blind pilot study. Rheumatol Int. 2013;33(11):2833-2838.
31. Ogrendik M. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial. Clin Ther. 2009;31(8):1754-1764.
32. Ogrendik M, Karagoz N. Treatment of rheumatoid arthritis with roxithromycin: a randomized trial. Postgrad Med. 2011;123(5): 220-227.
33. Zuckerman JM, Qamar F, Bono BR. Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am. 2009;23(4):997-1026
34. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997;61(3):377-392.
35. Martin SJ, Meyer JM, Chuck SK, Jung R, Messick CR, Pendland SL. Levofloxacin and sparfloxacin: new quinolone antibiotics. Ann Pharmacother. 1998;32(3):320-336.
36. Ogrendik M. Levofloxacin treatment in patients with rheumatoid arthritis receiving methotrexate. South Med J. 2007;100(2):135-139.
37. Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf. 2010;33(5):353-369.
38. Ogrendik M. Rheumatoid arthritis is an autoimmune disease caused by periodontal pathogens. Int J Gen Med. 2013;6:383-386.